Gefitinib
Cat. No.:YN340240
| 产品名称: | Gefitinib |
| CAS No.: | 184475-35-2 |
| Chemical Name: | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine |
| Synonyms: | 吉非替尼; ZD1839 |
| 分子量: | 446.90 |
| 分子式: | C₂₂H₂₄ClFN₄O₃ |
| SMILES: | ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Gefitinib (ZD1839) 是一种有效,选择性和口服活性的EGFR酪氨酸激酶抑制剂,IC50为 33 nM。Gefitinib 选择性抑制 EGF 刺激的肿瘤细胞生长 (IC50为 54 nM),并阻断 EGF 刺激的肿瘤细胞中EGFR自磷酸化。Gefitinib 还可诱导细胞自噬 (autophagy)。Gefitinib 具有抗肿瘤活性。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Mendelsohn, J., and Baselga, J.The EGF receptor family as targets for cancer therapyOncogene19(56),6550-6565(2000)
Ciardiello, F., Caputo, R., Bianco, R., et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitorClin. Cancer Res.6(5),2053-2063(2000)